argenx · ISIN: US04016X1019

argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 13.01.2025 | 06:00
13 January 2025 06:00AM
argenx Highlights 2025 Strategic Priorities
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales...
© Globe Newswire
06 January 2025 06:00AM
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 1...
© Globe Newswire
27 December 2024 06:00AM
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP...
© Globe Newswire
26 November 2024 06:00AM
argenx to Present at Upcoming Investor Conferences
November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December....
© Globe Newswire
20 November 2024 06:00AM
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
November 20, 2024, 7:00 AM CET...
© Globe Newswire
05 November 2024 06:00AM
argenx to Participate at Upcoming Investor Conferences
November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:...
© Globe Newswire
31 October 2024 06:00AM
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
$573 million in third quarter global net product sales...
© Globe Newswire
24 October 2024 05:00AM
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quar...
© Globe Newswire
15 October 2024 05:00AM
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response...
© Globe Newswire
19 September 2024 05:00AM
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
ADHERE was largest and most innovative clinical trial of CIDP patients to date...
© Globe Newswire
28 August 2024 05:00AM
argenx to Present at Upcoming Investor Conferences
August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:...
© Globe Newswire
25 July 2024 05:00AM
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
$478 million in second quarter global net product sales...
© Globe Newswire
18 July 2024 05:00AM
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 f...
© Globe Newswire
16 July 2024 04:30AM
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China...
© Globe Newswire
25 June 2024 08:30PM
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients...
© Globe Newswire
21 June 2024 08:50PM
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)...
© Globe Newswire
17 June 2024 05:00AM
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...
© Globe Newswire
04 June 2024 05:00AM
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June...
© Globe Newswire
09 May 2024 05:00AM
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
$398 million in first quarter global net product sales...
© Globe Newswire
07 May 2024 05:00AM
argenx to Present at BofA Securities 2024 Health Care Conference
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14,...
© Globe Newswire
02 May 2024 05:00AM
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 f...
© Globe Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.